Johnson & Johnson has announced the closure of its nearly 200,000 square-foot research and development (R&D) facility in the San Francisco Bay Area, less than 18 months after its opening in 9/22. The facility, situated in Brisbane as part of the San Francisco Bay Campus and the Healthpeak Properties-developed real estate project, was inaugurated in September 2022 with plans to house approximately 400 employees. The focus of the campus was on emerging gene and RNA-based therapies, as well as research on retinal and infectious diseases, aiming to double Johnson & Johnson's R&D presence in the Bay Area.
J&J to close Bay Area R&D site less than 18 months after opening https://t.co/qVJwHNVUmy
BMS Invests $400M in Ireland Campus for New Sterile Drug Product Facility Bristol Myers Squibb currently operates three commercial sites in Ireland. Learn more: https://t.co/a7HXSJHuhi https://t.co/Zzw8m2ECPZ
Johnson & Johnson is closing a facility it opened in the Healthpeak Properties-developed real estate project in 2022. https://t.co/pUothJPdgb
"The focus of the campus was emerging gene & RNA-based therapies, plus research on retinal & infectious diseases." When the facility opened in 9/22, the press release said they were doubling Johnson & Johnson's R&D presence in the Bay Area. 1/n https://t.co/VSN2cu07x7
Johnson & Johnson confirmed to @FierceBiotech @maxonwifi that they're closing their San Francisco Bay Campus/R&D facility in Brisbane which they opened in 9/22. ∼200K square feet & plans announced in '22 were for 400 employees to be based there. https://t.co/7F2VcmL3gr. https://t.co/poXdGkXI9Q
Breaking news: Johnson & Johnson is closing a massive, nearly 200,000 square-foot R&D facility in the Bay Area, less than 18 months after it opened. https://t.co/gVdsM09Cmd